Lutein-in-Extra-Virgin-Olive-Oil Supplementation as a Multifaceted Nutritional Intervention for Retinopathy of Prematurity: Evidence from the Mouse Oxygen-Induced Retinopathy Model
Open Access
Abstract
Background: Retinopathy of prematurity (ROP) is a predominant contributor to preventable childhood blindness driven by oxidative stress and inflammation, but with limited treatment options. Safe, non-invasive adjunctive strategies become attractive. Lutein displays antioxidant and anti-inflammatory properties, but its clinical efficacy remains controversial. We proposed that formulating lutein in extra-virgin olive oil (EVOO) might enhance its absorption and efficacy in ROP. Here, we evaluated the effects of lutein-in-EVOO (LEVOO) in oxygen-induced retinopathy (OIR), a mouse model of ROP. Methods: C57BL/6J mouse neonates received daily gavage of LEVOO (0.4 μg/g, 1.8 μg/g and 3.6 μg/g of lutein in EVOO) after OIR challenge from postnatal day (P) 12 to P16. Assessments were conducted at P17, including retinal vasculature, function, cytoarchitecture, inflammation, and oxidative damage; serum biochemical and antioxidant profiles; and proteomic analysis and targeted retinal metabolomic analysis. Results: Oral supplementation of LEVOO was well-tolerated and safe in mouse neonates. It reduced retinal avascular and neovascular areas, increased electroretinographic b-wave amplitudes, and restored amacrine cells and rod bipolar cells. LEVOO administration reduced oxidative damage and activated microglia. LEVOO administration inhibited the hypoxia-inducible factor-1α (HIF-1α)/macrophage migration inhibitory factor (MIF) signaling and low-density lipoprotein receptor-related protein-1 (LRP1)-dependent cyclophilin A (CypA)/matrix metalloproteinase-9 (MMP9) signaling. It also helped to partially restore retinal docosahexaenoic acid and dopamine in OIR mice. Conclusions: LEVOO demonstrated multifaceted efficacy in OIR. It reconstructed retinal vasculature, restored retinal function, and rescued neuronal cell loss with strong antioxidative and anti-inflammatory effects. Collectively, these findings establish LEVOO as a promising non-invasive complementary strategy for ROP.Keywords
Funding Information
- Health and Medical Research Fund (09201116)
This publication has 84 references indexed in Scilit:
- Fatty Acid Supplementation and Retinopathy of PrematurityJAMA Ophthalmology, 2026
- Arachidonic acid metabolism in health and diseaseMedcomm, 2023
- Association of Docosahexaenoic Acid and Arachidonic Acid Serum Levels With Retinopathy of Prematurity in Preterm InfantsJAMA Network Open, 2021
- Effect of Enteral Lipid Supplement on Severe Retinopathy of PrematurityJAMA Pediatrics, 2021
- Absence of macrophage migration inhibitory factor reduces proliferative retinopathy in a mouse modelActa Diabetologica, 2017
- Deficiency of aldose reductase attenuates inner retinal neuronal changes in a mouse model of retinopathy of prematurityGraefe's Archive for Clinical and Experimental Ophthalmology, 2015
- Lutein + Zeaxanthin and Omega-3 Fatty Acids for Age-Related Macular DegenerationJAMA, 2013
- Olive oil improves the intestinal absorption and bioavailability of lutein in lutein-deficient miceEuropean Journal of Nutrition, 2013
- Acutely increased cyclophilin a expression after brain injury: A role in blood‐brain barrier function and tissue preservationJournal of Neuroscience Research, 2007
- Immunocytochemical analysis of the mouse retinaJournal of Comparative Neurology, 2000